News

PharmExec1d
Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial
Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...
Fierce Pharma2d
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...
Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...
Devdiscourse4d
Blockbuster Diabetes Drugs Pioneer New Medical Frontiers
Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...